17 reports

The company is committed in helping families identify and manage genetic diseases.

  • Oncology
  • World
  • Market Size
  • Biocept, Inc.
  • Guardant Health, Inc.

THE COMPANY PRIMARILY FOCUSES ON RARE GENETIC DISORDERS, KIDNEY DISEASES, ORTHOPEDICS, ORGAN TRANSPLANT, CANCER, AND IMMUNE DISEASE.

  • Oncology
  • Latin America
  • Mexico
  • North America
  • Forecast

THE COMPANY PRIMARILY FOCUSES ON RARE GENETIC DISORDERS, KIDNEY DISEASES, ORTHOPEDICS, ORGAN TRANSPLANT, CANCER, AND IMMUNE DISEASE.

  • Oncology
  • Southern Europe
  • Spain
  • Forecast
  • Market Size

THE COMPANY PRIMARILY FOCUSES ON RARE GENETIC DISORDERS, KIDNEY DISEASES, ORTHOPEDICS, ORGAN TRANSPLANT, CANCER, AND IMMUNE DISEASE.

  • Oncology
  • Australasia
  • Australia
  • Oceania
  • Forecast

Update on the genetic engineering of regulatory T cells for the treatment of graft-versus-host-disease.

  • Oncology
  • Pharmaceutical
  • United States
  • Company
  • ZIOPHARM Oncology, Inc.

NPC IS A RARE AND FATAL GENETIC DISEASE CHARACTERIZED BY THE ACCUMULATION OF CHOLESTEROL IN CELLS AND TISSUES.

  • Oncology
  • Oxygen Device
  • Northern Europe
  • United Kingdom
  • Market Size

MOST OF THE WORLD' S ##, ## TO ##, ## RARE DISEASES ARE GENETIC.

  • Hospital
  • Oncology
  • Canada
  • North America
  • Medtronic, Inc.

It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections.

  • Oncology
  • Southern Europe
  • Spain
  • Market Size
  • Grifols, S.A.

AS PART OF THIS AGREEMENT, ALNYLAM WILL ADVANCE AN ADDITIONAL INVESTIGATIONAL ASSET IN AN UNDISCLOSED RARE GENETIC DISEASE THROUGH THE END OF IND-ENABLING STUDIES.

  • Hospital
  • Oncology
  • France
  • Western Europe
  • Market Size

The role of liver biopsy has changed over the years from a diagnostic tool for suspected liver disease to one of prognosis and evaluation of therapeutic strategies, mainly due to advances in serologic diagnosis of viral/ autoimmune hepatitis and laboratory tests for

  • Hospital
  • Oncology
  • Europe
  • United Kingdom
  • Forecast

The prominent features of this report are - ##.

  • Clinical Trial
  • Lymphoma
  • Oncology
  • United States
  • World

## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Actinium Pharmaceuticals Inc ## ## ## ## ## ## SymBio Pharmaceuticals Ltd ## ## ## ## ## ## Sanofi ## ## ## ## ## ## Onconova Therapeutics Inc ## ## ## ## ## ## Nohla Therapeutics Inc ## ## ##

  • Blood Disease
  • Cell Therapy
  • Oncology
  • World
  • Celgene Corporation

The prominent features of this report are - ##.

  • Clinical Trial
  • Leukemia
  • Monoclonal Antibody
  • Oncology
  • Novartis AG

THE COMPANY PRIMARILY FOCUSES ON RARE GENETIC DISORDERS, KIDNEY DISEASES, ORTHOPEDICS, ORGAN TRANSPLANT, CANCER, AND IMMUNE DISEASE.

  • Oncology
  • Canada
  • North America
  • Forecast
  • Market Size

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Leukemia
  • Oncology
  • Novartis AG
  • Clinical Trial profile. 17 Trial Title

The prominent features of this report are - ##.

  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Celgene Corporation

About BPX-## BPX-## is an adjunct T-cell therapy administered after allogeneic HSCT, comprising genetically modified donor T cells incorporating Bellicum' s CaspaCIDe® safety switch.

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative